The Semaglutide-to-Retatrutide Shift: A Researcher's Reading List

The incretin research field has moved through three generations in under two decades: single-receptor GLP-1 agonists, dual GIP/GLP-1 agonists, and now triple agonists that add glucagon receptor activity. Each generation has produced larger reported effects on body weight and glycemic markers in clinical trials, and each has raised a new set of mechanistic questions. For researchers tracking this progression, the published literature on semaglutide, tirzepatide, and retatrutide forms a near-linear reading list — with the most recent entries still being written.

The single-agonist baseline: what semaglutide established

Semaglutide is a long-acting GLP-1 receptor agonist originally developed for type 2 diabetes and later studied for chronic weight management. The STEP program — a series of phase 3 trials published between 2021 and 2023 — reported mean weight reductions in the range of roughly 15% from baseline at 68 weeks in adults with obesity, with accompanying improvements in HbA1c, systolic blood pressure, and several lipid fractions. The SELECT cardiovascular outcomes trial, reported by Lincoff and colleagues in 2023, extended the picture by reporting a reduction in major adverse cardiovascular events in participants with established cardiovascular disease and overweight or obesity.

Mechanistically, semaglutide acts primarily on GLP-1 receptors expressed in pancreatic beta cells, the central nervous system, and the gastrointestinal tract. Reported effects include glucose-dependent insulin secretion, slowed gastric emptying, and central appetite suppression through hypothalamic and brainstem circuits. In published pharmacokinetic work, the molecule's half-life of approximately one week is attributed to albumin binding via a fatty acid side chain and to substitutions that reduce DPP-4 degradation.

The single-agonist era also established the tolerability template that later agents would be measured against. Gastrointestinal adverse events — nausea, vomiting, diarrhea, and constipation — were the most commonly reported treatment-emergent findings in the STEP trials, typically concentrated during dose escalation. Rarer signals around pancreatitis, gallbladder disease, and thyroid C-cell tumors in rodent models were flagged in regulatory documentation and continue to be studied. Researchers reviewing newer triple agonists generally use this adverse-event profile as the reference point.

The dual-agonist step: tirzepatide and the GIP question

Tirzepatide added glucose-dependent insulinotropic polypeptide (GIP) receptor activity to GLP-1 agonism in a single molecule. In the SURPASS trials in type 2 diabetes and the SURMOUNT trials in obesity, investigators reported HbA1c reductions and weight reductions that exceeded those seen historically with GLP-1 monoagonists. SURMOUNT-1, published by Jastreboff and colleagues in 2022, reported mean weight reductions of roughly 15%, 20%, and 21% at 72 weeks at the 5 mg, 10 mg, and 15 mg weekly doses respectively, versus approximately 3% with placebo.

The interpretation of GIP's contribution is itself an active research area. Classical work in the 1990s and early 2000s suggested GIP receptor agonism alone had minimal effect on body weight and, in some rodent models, was associated with weight gain rather than loss. More recent work — including studies from Müller, Finan, and collaborators — has proposed that GIP receptor activity in central nervous system regions and in adipose tissue may complement GLP-1 signaling, potentially by modulating nausea thresholds and by affecting adipocyte lipid handling. Whether GIP agonism, GIP antagonism, or some signaling bias is responsible for the incremental effects observed with Tirzepatide is, in published reviews, still described as unsettled.

From a researcher's standpoint, Tirzepatide's clinical dataset is now substantial enough to serve as a second reference point. It extends the GLP-1 benchmark without replacing it, and it introduces the notion — later amplified by retatrutide — that combining incretin receptor activities in a single peptide can yield effects that are not simply additive with monoagonist data.

The triple-agonist hypothesis: adding glucagon

Retatrutide extends the combinatorial approach by adding agonism at the glucagon receptor to GIP and GLP-1 activity. On first reading, adding glucagon activity to a weight-management compound seems counterintuitive — glucagon is historically associated with hepatic glucose output and hyperglycemia. The hypothesis underlying triple-agonist design, developed across work by Finan, DiMarchi, Tschöp, and collaborators in the 2010s, is that low-level glucagon receptor activity increases energy expenditure and promotes hepatic lipid oxidation, while concurrent GLP-1 activity offsets the glycemic effect by driving insulin secretion and suppressing appetite.

The phase 2 trial in obesity, reported by Jastreboff and colleagues in the New England Journal of Medicine in 2023, described mean weight reductions at 48 weeks of approximately 17% at 4 mg weekly, approximately 22% at 8 mg, and approximately 24% at 12 mg, compared with roughly 2% on placebo. The curves in the published figures had not clearly plateaued at the end of the treatment period, which several editorialists noted as unusual for weight-loss pharmacology at this scale. A separate phase 2 trial in type 2 diabetes, published in The Lancet in the same year by Rosenstock and colleagues, reported HbA1c reductions and weight reductions consistent with the obesity data.

A phase 2 study in metabolic dysfunction-associated steatotic liver disease (MASLD), reported by Sanyal and colleagues in 2024, described reductions in liver fat content measured by MRI-PDFF that were larger than those historically reported with GLP-1 monoagonists at comparable exposure durations. Researchers interested in hepatic endpoints have cited that study as preliminary evidence that the glucagon receptor contribution may be particularly relevant in the liver — though the trial was not designed or powered for histological endpoints, and confirmatory phase 3 work is ongoing.

Why the adipose tissue argument matters

Much of the mechanistic interest in triple agonism concentrates on adipose tissue. In published rodent work from the Tschöp and DiMarchi groups, unimolecular GIP/GLP-1/glucagon agonists produced reductions in fat mass that were greater than reductions attributable to food-intake suppression alone, suggesting a component of increased energy expenditure or altered substrate utilization. Indirect calorimetry data in those animal studies reported elevated oxygen consumption during the active phase, and gene-expression data in white and brown adipose tissue reported changes consistent with enhanced lipid oxidation.

Whether these rodent findings translate quantitatively to humans is one of the field's open questions. Human indirect calorimetry data on retatrutide is sparse in the published literature as of this writing. The phase 2 obesity trial reported changes in body composition by DXA in a subset of participants, with the authors noting that a substantial proportion of the weight lost was fat mass rather than lean mass. Those DXA findings are consistent with, but not proof of, an adipose-specific mechanism.

For researchers comparing compounds, the practical question is whether the triple-agonist profile changes the ratio of fat mass loss to lean mass loss, or changes regional fat distribution — particularly visceral versus subcutaneous — relative to dual or single agonists. Published head-to-head trials addressing this directly do not yet exist; the comparisons currently rely on cross-trial inference, which is methodologically limited.

What the reading list should include

A researcher assembling a literature review on this progression can reasonably organize the reading chronologically and by receptor combination. A minimum set of entries would include:

• Foundational GLP-1 pharmacology papers from the Holst and Drucker laboratories, spanning the late 1990s through the 2010s.
• The SUSTAIN, STEP, and SELECT trial reports on semaglutide.
• The SURPASS and SURMOUNT trial reports on tirzepatide, along with mechanistic reviews of GIP receptor biology from Müller, Finan, and collaborators.
• The retatrutide phase 2 obesity, type 2 diabetes, and MASLD trial reports from 2023–2024.
• The unimolecular multi-agonist design papers from Finan, DiMarchi, and Tschöp (2013 onward), which describe the preclinical rationale.
• Review articles on glucagon receptor biology, including historical work on glucagon's effects on hepatic lipid metabolism and energy expenditure.

The gaps in the current literature are also worth cataloguing explicitly. There are, as of this writing, no published phase 3 retatrutide trial results in peer-reviewed form; no published head-to-head trials against tirzepatide or semaglutide at matched exposures; limited human data on body-composition outcomes beyond DXA subsets; and limited long-term safety data beyond the phase 2 follow-up windows. Researchers reviewing this compound class should treat the triple-agonist evidence as preliminary and trial-based, not as established clinical knowledge.

Mechanism differences in a single frame

It can help to summarize the three generations in mechanistic shorthand, with the caveat that shorthand always oversimplifies.

• Semaglutide (GLP-1): glucose-dependent insulin secretion; central appetite suppression; slowed gastric emptying. Weight reductions reported around 15% at phase 3 doses.
• Tirzepatide (GIP + GLP-1): GLP-1 effects plus GIP receptor activity, which in published work may contribute through central and adipose mechanisms that remain under investigation. Weight reductions reported around 20–22% at the higher phase 3 doses.
• Retatrutide (GIP + GLP-1 + glucagon): adds glucagon receptor agonism, hypothesized to increase energy expenditure and hepatic lipid oxidation. Weight reductions reported up to approximately 24% at 48 weeks in phase 2, with the dose-response curve not clearly plateaued.

The numerical progression from roughly 15% to roughly 20% to roughly 24% is striking, but researchers reading the trials will note that populations, durations, and escalation schemes differ across studies. The step changes are not strictly comparable, and the field's more cautious commentators have flagged the need for within-trial, head-to-head comparisons before the progression can be described as a true dose-response in receptor complexity.

Open questions

Several questions remain unresolved in the public literature.

• Long-term cardiovascular outcomes for tirzepatide and retatrutide are not yet reported; the semaglutide SELECT data does not straightforwardly extend to compounds with different receptor profiles.
• The relative contribution of each receptor in tirzepatide and retatrutide remains inferred rather than directly measured in humans; receptor-selective antagonist co-administration studies in humans are sparse.
• Hepatic outcomes — particularly histological endpoints in MASLD and MASH — are under active phase 3 investigation but not yet reported in peer-reviewed form for retatrutide.
• Body composition effects, including visceral-versus-subcutaneous fat distribution and lean mass preservation, are reported only in trial subsets, and direct comparisons across the three compounds do not yet exist.
• Durability of effect after discontinuation — a well-characterized limitation of semaglutide in the STEP 4 extension — has not been comprehensively reported for tirzepatide or retatrutide at matched follow-up.

For researchers tracking this compound class, the practical implication is that the reading list is still being written. The peer-reviewed record supports a clear statement that triple-agonist peptides have produced larger phase 2 weight and metabolic effects than earlier-generation incretin agents in the trials published to date. It does not yet support stronger claims about mechanism, durability, or comparative safety. Those entries in the reading list are, for now, forthcoming.